Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

Sorted by: relevance · author · university · dateNew search

You searched for subject:(miRNA mimic). Showing records 1 – 2 of 2 total matches.

Search Limiters

Last 2 Years | English Only

No search limiters apply to these results.

▼ Search Limiters

1. Pozniak, John. Systemic Delivery of microRNA as a Therapeutic Modality to Treat Cancer.

Degree: MS, Medicine: Molecular and Developmental Biology, 2013, University of Cincinnati

MicroRNAs (miRNA) are small noncoding RNAs with an important role in the initiation and progression of human cancers by posttranscriptional regulation of tumors suppressors and oncogenes. Recent evidence showing miRNAs are aberrantly expressed in tumors underscores them as potential targets for therapeutic intervention. The rationale for developing miRNA-based cancer therapeutics is based on correcting miRNA expression by either antagonism or miRNA replacement in tumors that may provide therapeutic benefit. This article surveys the present knowledge of cancer-associated miRNAs and considers advantages and potential challenges of current delivery technologies employed to systemically deliver miRNAs to tumors by experimental and pre-clinical studies that have used these approaches. Advisors/Committee Members: Starczynowski, Daniel (Committee Chair).

Subjects/Keywords: Oncology; miRNA; Cancer; AntagomiR; Systemic Delivery; Mimic; Replacement Therapy

…Detectable miRNA in the plasma and serum of cancer patients may provide a useful non-invasive tool… …disease progression and drug resistance that may lead to the development of miRNA based… …therapeutics. miRNA Therapeutics Depending on miRNA function and status in diseased tissue, two… …approaches have emerged towards the development of miRNA-based cancer therapeutics: miRNA… …antagonists and miRNA mimics. miRNA antagonists function by inhibiting endogenous miRNAs by high… 

Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Pozniak, J. (2013). Systemic Delivery of microRNA as a Therapeutic Modality to Treat Cancer. (Masters Thesis). University of Cincinnati. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=ucin1367939186

Chicago Manual of Style (16th Edition):

Pozniak, John. “Systemic Delivery of microRNA as a Therapeutic Modality to Treat Cancer.” 2013. Masters Thesis, University of Cincinnati. Accessed January 23, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1367939186.

MLA Handbook (7th Edition):

Pozniak, John. “Systemic Delivery of microRNA as a Therapeutic Modality to Treat Cancer.” 2013. Web. 23 Jan 2020.

Vancouver:

Pozniak J. Systemic Delivery of microRNA as a Therapeutic Modality to Treat Cancer. [Internet] [Masters thesis]. University of Cincinnati; 2013. [cited 2020 Jan 23]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1367939186.

Council of Science Editors:

Pozniak J. Systemic Delivery of microRNA as a Therapeutic Modality to Treat Cancer. [Masters Thesis]. University of Cincinnati; 2013. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1367939186


Universitat Pompeu Fabra

2. Guidi, Mònica. Micro RNA-Mediated regulation of the full-length and truncated isoforms of human neurotrophic tyrosine kinase receptor type 3 (NTRK 3).

Degree: Departament de Ciències Experimentals i de la Salut, 2009, Universitat Pompeu Fabra

Las neurotrofinas y sus receptores constituyen una familia de factores cruciales para el desarrollo del sistema nervioso. La neurotrofina 3 ejerce su función principalmente a través de una unión de gran afinidad al receptor NTRK3, del cual se conocen dos isoformas principales, una larga de 150KDa con actividad de tipo tirosina kinasa y una truncada de 50KDa sin dicha actividad. Estas dos isoformas no comparten la misma región 3'UTR, lo que sugiere la existencia de una regulación postranscripcional diferente. En el presente trabajo se ha explorado como los microRNAs intervienen en la regulación de NTRK3, demostrando que las dos isoformas son reguladas por diferentes miRNAs. Se han analizado las consecuencias fisiológicas de la sobrexpresión de dichos microRNAs utilizando células de neuroblastoma. Finalmente, se ha estudiado la posible implicación del microRNA miR-124 en el control del splicing alternativo de NTRK3 a través de la regulación de represor de splicing PTBP1. Advisors/Committee Members: [email protected] (authoremail), true (authoremailshow), Espinosa Parrilla, Yolanda (director), Estivill, Xavier, 1955- (director).

Subjects/Keywords: RISC complex; retinoic acid; renilla luciferase; real-time quantitative PCR; PTBP1; pri-miRNA; pre-miRNA; post-transcriptional regulation; piRNA; PicTar; pGL4.13; PCR; P-body; p75NTR; overexpression; NTRK3; NTRK2; NTRK1; non-coding RNAs; NGF; neurotrophin; neurotrophic signaling; neuronal differentiation; neurodevelopment; neuroblastoma; nervous system; mRNA; miRNA target prediction; miRNA profiling; miRNA mimic; miRNA microarray; miRNA inhibitor; miRanda; microRNA; microarray; luciferase assay; Ingenuity Pathway Analysis (IPA); heLa cells; gene silencing; gene regulation; full-length isoform (FL-NTRK3); firefly luciferase; ERK; disease; dicer; cancer development; BDNF; argonaute; alternative splicing; 3'UTR; RNAhybrid; RT-PCR; SH-SY5Y cells; siRNA; standard error; synaptic plasticity; target validation; TargetScan; transfection; translational repression; TrkA; TrkB; TrkC; truncated isoform (TR-NTRK3); tyrosine kinase (TK); western blot; 575; 61

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Guidi, M. (2009). Micro RNA-Mediated regulation of the full-length and truncated isoforms of human neurotrophic tyrosine kinase receptor type 3 (NTRK 3). (Thesis). Universitat Pompeu Fabra. Retrieved from http://hdl.handle.net/10803/7114

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Guidi, Mònica. “Micro RNA-Mediated regulation of the full-length and truncated isoforms of human neurotrophic tyrosine kinase receptor type 3 (NTRK 3).” 2009. Thesis, Universitat Pompeu Fabra. Accessed January 23, 2020. http://hdl.handle.net/10803/7114.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Guidi, Mònica. “Micro RNA-Mediated regulation of the full-length and truncated isoforms of human neurotrophic tyrosine kinase receptor type 3 (NTRK 3).” 2009. Web. 23 Jan 2020.

Vancouver:

Guidi M. Micro RNA-Mediated regulation of the full-length and truncated isoforms of human neurotrophic tyrosine kinase receptor type 3 (NTRK 3). [Internet] [Thesis]. Universitat Pompeu Fabra; 2009. [cited 2020 Jan 23]. Available from: http://hdl.handle.net/10803/7114.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Guidi M. Micro RNA-Mediated regulation of the full-length and truncated isoforms of human neurotrophic tyrosine kinase receptor type 3 (NTRK 3). [Thesis]. Universitat Pompeu Fabra; 2009. Available from: http://hdl.handle.net/10803/7114

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

.